The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination (original) (raw)

• Lollini, P.L., Cavallo, F., Nanni, P. & Forni, G. Vaccines for tumour prevention. Nat. Rev. Cancer 6, 204–216 (2006).
  Article CAS Google Scholar
• Biragyn, A. & Kwak, L.W. Designer cancer vaccines are still in fashion. Nat. Med. 6, 966–968 (2000).
  Article CAS Google Scholar
• Dar, M.M. & Kwak, L.W. Vaccination strategies for lymphomas. Curr. Oncol. Rep. 5, 380–386 (2003).
  Article Google Scholar
• Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8, 11–23 (2008).
  Article CAS Google Scholar
• Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non–small-cell lung cancer. Nature 448, 561–566 (2007).
  Article CAS Google Scholar
• Dirks, W.G. et al. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 100, 49–56 (2002).
  Article CAS Google Scholar
• Perez-Pinera, P., Chang, Y., Astudillo, A., Mortimer, J. & Deuel, T.F. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem. Biophys. Res. Commun. 358, 399–403 (2007).
  Article CAS Google Scholar
• Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915 (2004).
  Article CAS Google Scholar
• Radford, K.J., Vari, F. & Hart, D.N. Vaccine strategies to treat lymphoproliferative disorders. Pathology 37, 534–550 (2005).
  Article CAS Google Scholar
• Duyster, J., Bai, R.Y. & Morris, S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20, 5623–5637 (2001).
  Article CAS Google Scholar
• Pulford, K. et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96, 1605–1607 (2000).
  CAS PubMed Google Scholar
• Passoni, L. et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99, 2100–2106 (2002).
  Article CAS Google Scholar
• Ait-Tahar, K. et al. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int. J. Cancer 118, 688–695 (2006).
  Article CAS Google Scholar
• Ait-Tahar, K., Barnardo, M.C. & Pulford, K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res. 67, 1898–1901 (2007).
  Article CAS Google Scholar
• Passoni, L. & Gambacorti-Passerini, C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk. Lymphoma 44, 1675–1681 (2003).
  Article CAS Google Scholar
• Chiarle, R. et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623–629 (2005).
  Article CAS Google Scholar
• Wang, Z. et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11, 711–721 (2004).
  Article CAS Google Scholar
• Scheich, F., Duyster, J., Peschel, C. & Bernhard, H. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 110, 2556–2560 (2007).
  Article CAS Google Scholar
• Chiarle, R. et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101, 1919–1927 (2003).
  Article CAS Google Scholar
• Egloff, A.M., Vella, L.A. & Finn, O.J. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res. 66, 6–9 (2006).
  Article CAS Google Scholar
• Williams, D.M. et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br. J. Haematol. 117, 812–820 (2002).
  Article CAS Google Scholar
• Yu, M. & Finn, O.J. DNA vaccines for cancer too. Cancer Immunol. Immunother. 55, 119–130 (2006).
  Article Google Scholar
• Packard, B.Z., Telford, W.G., Komoriya, A. & Henkart, P.A. Granzyme B activity in target cells detects attack by cytotoxic lymphocytes. J. Immunol. 179, 3812–3820 (2007).
  Article CAS Google Scholar
• Jaffe, E.S. Mature T-cell and NK-cell lymphomas in the pediatric age group. Am. J. Clin. Pathol. 122, S110–S121 (2004).
  Article Google Scholar
• Rizvi, M.A., Evens, A.M., Tallman, M.S., Nelson, B.P. & Rosen, S.T. T-cell non-Hodgkin lymphoma. Blood 107, 1255–1264 (2006).
  Article CAS Google Scholar
• Vernersson, E. et al. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448–461 (2006).
  Article CAS Google Scholar
• Piva, R. et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107, 689–697 (2006).
  Article CAS Google Scholar
• Wan, W. et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107, 1617–1623 (2006).
  Article CAS Google Scholar
• Qin, Z. et al. B cells inhibit induction of T cell–dependent tumor immunity. Nat. Med. 4, 627–630 (1998).
  Article CAS Google Scholar
• Ingulli, E. Tracing tolerance and immunity in vivo by CFSE-labeling of administered cells. Methods Mol. Biol. 380, 365–376 (2007).
  Article CAS Google Scholar